Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diphtheria tetanus acellular pertussis vaccine - BioNet-Asia

Next Previous
Drug Profile

Diphtheria tetanus acellular pertussis vaccine - BioNet-Asia

Alternative Names: Boostagen; DTaP; DTaP - BioNet-Asia; DTaP combos; Recombinant DTaP

Latest Information Update: 29 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNet-Asia
  • Developer BioNet-Asia; Mahidol University
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 07 Nov 2022 Diphtheria tetanus acellular pertussis vaccine is still in phase III trials for Diphtheria (In adults, In the elderly, Prevention) in Thailand (IM) (TCTR20190927006)
  • 07 Nov 2022 Diphtheria tetanus acellular pertussis vaccine is still in phase III trials for Pertussis (In adults, In the elderly, Prevention) in Thailand (IM) (TCTR20190927006)
  • 07 Nov 2022 Diphtheria tetanus acellular pertussis vaccine is still in phase III trials for Tetanus (In adults, In the elderly, Prevention) in Thailand (IM) (TCTR20190927006)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top